Immunocore reports second quarter financial results and provides a business update
08 août 2024 07h00 HE
|
Immunocore Holdings plc
KIMMTRAK® (tebentafusp-tebn) net revenues of $75.3 million in 2Q 2024 driven by US growth Registrational Phase 3 TEBE-AM trial with KIMMTRAK in previously treated cutaneous melanoma ongoing,...
Immunocore to report second quarter 2024 financial results and host call on August 8, 2024
01 août 2024 07h00 HE
|
Immunocore Holdings plc
Immunocore to report second quarter 2024 financial results and host call on August 8, 2024 (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 01 August 2024) Immunocore...
Immunocore announces randomization of first patient in the global, registrational Phase 3 clinical trial testing brenetafusp for the treatment of first-line advanced or metastatic cutaneous melanoma
18 juin 2024 07h00 HE
|
Immunocore Holdings plc
Immunocore announces randomization of first patient in the global, registrational Phase 3 clinical trial testing brenetafusp for the treatment of first-line advanced or metastatic cutaneous melanoma ...
Immunocore presents KIMMTRAK clinical data demonstrating that patients with stable disease and confirmed tumor reduction have similar clinical outcomes to patients with partial response
01 juin 2024 08h00 HE
|
Immunocore Holdings plc
Immunocore presents KIMMTRAK clinical data demonstrating that patients with stable disease and confirmed tumor reduction have similar clinical outcomes to patients with partial response Data were...
Immunocore converts Phase 2/3 TEBE-AM clinical trial into registrational Phase 3 trial evaluating KIMMTRAK for previously treated advanced cutaneous melanoma
29 mai 2024 07h00 HE
|
Immunocore Holdings plc
Immunocore converts Phase 2/3 TEBE-AM clinical trial into registrational Phase 3 trial evaluating KIMMTRAK for previously treated advanced cutaneous melanoma Following recent consultation with FDA,...
Immunocore announces upcoming presentation and posters at ASCO 2024
24 avr. 2024 10h00 HE
|
Immunocore Holdings plc
Immunocore announces upcoming presentation and posters at ASCO 2024 Phase 1 expansion data in immune checkpoints pre-treated cutaneous melanoma for brenetafusp (IMC-F106C targeting PRAME) to be...
Immunocore to present at upcoming investor conferences
04 avr. 2024 16h00 HE
|
Immunocore Holdings Limited
Immunocore to present at upcoming investor conferences (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 04 April 2024) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore”...
Immunocore presented two posters at CROI 2024
05 mars 2024 16h30 HE
|
Immunocore Holdings Limited
Immunocore presented two posters at CROI 2024 Preclinical data highlights importance of TCR biology in development of new HIV treatments (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. &...
Immunocore to present at upcoming investor conferences
01 mars 2024 07h00 HE
|
Immunocore Holdings Limited
Immunocore to present at upcoming investor conferences (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 01 March 2024) Immunocore Holdings plc (Nasdaq: IMCR)...
Immunocore reports fourth quarter and full year 2023 financial results and provides a business update
28 févr. 2024 07h34 HE
|
Immunocore Holdings Limited
Immunocore reports fourth quarter and full year 2023 financial results and provides a business update KIMMTRAK (tebentafusp) net revenues of $67.6 million in Q4 2023 and $238.7 million in 2023;...